Archives May 2026

Business Wire India

TechD Cybersecurity Limited (NSE SME: TECHD), a CERT-In empaneled MSSP serving over 500 enterprise clients, today announced the launch of TECHD ONE, AI-native unified cybersecurity platform, now live at techdefence.ai. The platform converges four AI-driven security modules into a single operational fabric, eliminating the tool sprawl and integration debt that have historically fragmented enterprise cyber defence in India.

 

TECHD ONE Phase 1 launches with four production-ready modules:

 

• Dark Vector AI – AI-powered autonomous external attack surface management and dark-web, Deep-web threat intelligence and brand protection suite.
• Provenance AI – AI Native enterprise software supply chain platform for Zero-day Discovery, Source code review, SCA, SBOM, AI-powered remediation, powered by Eagle, Lion, and Griffin models, powered by Safeguard.sh’s strategic collaboration.
• Human Trust AI – AI-powered behavioral risk intelligence covering phishing, vishing, smishing and insider threats.
• OT Shield AI – Vulnerability Intelligence for operational-technology and ICS security for industrial and critical-infrastructure environments.

 

“For two decades, Indian enterprises have bought point products that don’t talk to each other, running on AI models they don’t control, hosted on infrastructure they cannot audit. TECHD, ONE rewrites that contract. It is a single AI-native platform, built on indigenous models, delivered with the trust profile Indian regulators and enterprise boards are now demanding. This is what sovereign cybersecurity should look like.”

 

— Sunny Vaghela, Founder and Managing Director, TechD Cybersecurity Limited

 

TechD Cybersecurity serves customers that include the Adani Group, JM Financial, Zensar Technologies, and Astral Limited. The company’s IPO in September 2025 was oversubscribed 718 times, among the most heavily subscribed cybersecurity listings in Indian capital-markets history.

 

TECHD ONE will expand through Phase 1 from this quarter and Phase 2 modules — SecOps AI, PrivacyOps AI, and Identity Guard which are under development in 2027 – alongside a parallel “Cybersecurity for AI” track that secures AI systems themselves, including LLM security scanning, AI runtime protection, AI red-teaming, AI VAPT, and ISO/IEC 42001 advisory services.

 

The new techdefence.ai property will serve as the platform’s customer portal, technical documentation hub, and AI model transparency center.

Business Wire India

 

The film is a pioneering effort in conveying the legacy of one of India’s largest business groups through tech-backed storytelling. It is also potentially a pathway for future films on creative retelling of the past.

Business Wire India

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend.

 

The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026.

 

 

Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to undertake to receive the Dividend, please contact the Information Agent:

 

 

D.F. King & Co., Inc.
28 Liberty Street, 53rd Floor
New York, NY 10005
Attention: Sinovac Biotech Ltd. Special Dividend
Email: sva@dfking.com, with a subject line of Sinovac Biotech Ltd, Special Dividend

 

 

About SINOVAC

 

 

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

 

 

The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive^®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

 

 

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu^®), the world’s first H1N1 influenza vaccine (Panflu.1^®), and CoronaVac^®, the most widely used inactivated COVID-19 vaccine globally.

 

 

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

 

 

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

 

 

For more information, please see the Company’s website at www.sinovac.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520175565/en/

 

Business Wire India

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment

 

Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline

 

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm).

 

Continuing to raise the bar in CLL

 

 

At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL.

 

 

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:

 

 

“Seventy-eight-month follow-up data from SEQUOIA underscore what it truly takes to lead in CLL over the long term: long-term efficacy, ability for sequencing treatments, and confidence in first-line treatment decisions. Building on that leadership, we’re excited to be rapidly advancing the next generation of medicines, including sonrotoclax-based combinations and our BTK degrader BGB-16673, which are designed to extend what is possible for patients across lines of therapy.”

 

 

Key data presentations in CLL include:

 

 

• New results from the SEQUOIA trial with 78 months follow-up reinforce BRUKINSA^® (zanubrutinib) as the foundational BTK inhibitor in CLL, with durable disease control that continues to raise expectations for what patients and physicians should expect from first-line therapy over the long term. Data will be presented at both ASCO and EHA.
• A subgroup analysis of SEQUOIA, which includes one of the largest and longest-followed cohorts of patients aged ≥80 years ever reported in a Phase 3 CLL study, showing that age did not limit benefit. Data will be presented at EHA 2026.
• Oral presentation at EHA 2026 of updated data of BeOne’s foundational BTK degrader – BGB-16673 – in patients with R/R CLL, demonstrating promising and durable activity and a manageable safety profile. An additional poster will be shared featuring never-before-presented data of BGB-16673 in BTK-naïve patients. BGB-16673 is the most advanced BTK degrader in the clinic, with more than 1,100 patients dosed.
• Data from the all-oral combination of BeOne’s foundational BCL2 inhibitor sonrotoclax plus zanubrutinib (ZS) in CLL, which demonstrated deep responses, unprecedented speed to undetectable MRD, and durable remissions and a generally well-tolerated safety profile. These data reinforce the potential for a next-generation, time-limited approach designed to deliver long-term outcomes without compromising durability or safety. Data will be presented as a poster at ASCO 2026 and an oral presentation at EHA 2026.

 

 

Accelerating a high-potential solid tumor portfolio

 

BeOne is highlighting strong momentum across its deep and diverse solid tumor portfolio at ASCO, with seven unique assets featured in three oral presentations and eight posters. These data span both in-line and pipeline therapies, including results demonstrating the differentiated profile of PD-1 inhibitor TEVIMBRA^® (tislelizumab) across lung and gastrointestinal cancers, as well as in combination with the novel HER2-targeting agent ZIIHERA^® (zanidatamab). The Company’s development superhighway is accelerating progress across all stages of development, generating compelling clinical data that support the potential of these therapies to reshape treatment in areas of high unmet need.

 

 

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said:

 

 

“At ASCO 2026, we are demonstrating the strength of BeOne’s science, the scale of our pipeline, and the speed at which we are delivering innovation for patients. With multiple programs moving simultaneously toward pivotal trials, we are building durable disease leadership across breast, gynecologic, lung and gastrointestinal cancers – areas where substantial unmet patient need remains.”

 

 

Key data presentations across our solid tumor programs include:

 

 

• First disclosure of anti-tumor effects and safety/tolerability profile of the highly selective CDK4 inhibitor BGB-43395 Phase 1 treatment data in first-line HR-positive/HER2-negative breast cancer.
• Rapid oral presentation on BG-C9074, a promising B7-H4-targeting ADC, with Phase 1 dose escalation and safety expansion data.
• Rapid oral presentation on BGB-B2033, a potentially first-in-class GPC3 x 4-1BBbispecific antibody, with first clinical data of a Phase 1 study in heavily pre-treated hepatocellular carcinoma patients.
• Rapid oral presentation with a PD-L1 subgroup analysis of the HERIZON-GEA-01 trial in which TEVIMBRA in combination with ZIIHERA and chemotherapy demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) in patients with HER2+ gastroesophageal adenocarcinoma, irrespective of PD-L1 expression (in partnership with Jazz Pharmaceuticals).

 

 

Investor webcast to highlight pipeline data at ASCO

 

BeOne will host an investor webcast on June 1, 2026, at 7:00 PM CDT/8:00 PM EDT, led by John V. Oyler, Co-Founder, Chairman, and CEO, alongside the Company’s leadership team and invited key opinion leaders. The webcast will review clinical and corporate highlights from ASCO, provide updates on BeOne’s global R&D pipeline and platforms, and discuss the strategic priorities and execution capabilities driving the Company’s long-term growth.

 

 

Webcast access details are available in the Investors section of BeOne’s website at http://ir.beonemedicines.com, https://hkexir.beonemedicines.com, and https://sseir.beonemedicines.com. An archived webcast will be available on the Company’s website.

 

 

Full list of BeOne’s presentations at ASCO:

 

 

Hematology

 

 

BRUKINSA^® (Zanubrutinib)

 

 

Abstract Title	Presentation Details	Lead Author
Subsequent therapies and time to second progression-free survival events in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab in SEQUOIA	Poster Presentation: 544       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Constantine S. Tam
Navigating the post–covalent Bruton tyrosine kinase inhibitor landscape in mantle cell lymphoma: Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization	Poster Presentation: 556       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Alvaro Alencar
Real-world outcomes among Medicare beneficiaries treated with first-line Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia	Poster Presentation: 545       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Daniel A. Ermann
Real-world impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization in patients with chronic lymphocytic leukemia	Poster Presentation: 540       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Michael Fradley
Real-world treatment survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States	Poster Presentation: 543       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Ryan Jacobs
A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States	Poster Presentation: 560       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Yucai Wang
Incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib	Abstract Number: e19020	Ryan Jacobs
Risk factors for second primary malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world study	Abstract Number: e19022	Lili Zhou
Characterizing patient self-reported adherence to BTKis and symptoms in CLL/SLL using an electronic patient-reported outcomes platform	Abstract Number: e19030	Mustafa Ascha
Real-world treatment utilization, sequencing patterns, and healthcare resource utilization in Waldenström macroglobulinemia	Abstract Number: e19056	Jorge Castillo

 

Sonrotoclax

 

Abstract Title	Presentation Details	Lead Author
First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53	Poster Presentation: 541       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Constantine S. Tam
Sonrotoclax + zanubrutinib vs venetoclax + acalabrutinib in treatment-naive chronic lymphocytic leukemia: A phase 3 randomized trial design (CELESTIAL-TNCLL-2)	Poster Presentation: 596a       Session Title: Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia       Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT	Mazyar Shadman
Efficacy of sonrotoclax vs pirtobrutinib in post–Bruton tyrosine kinase inhibitor relapsed/refractory mantle cell lymphoma: An indirect comparison	Abstract Number: e19050	Alvaro Alencar

 

 

Solid Tumors

 

BGB-43395 (CDK4i)

 

 

Abstract Title	Presentation Details	Lead Author
First disclosure of frontline treatment with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer: A phase 1 safety expansion	Poster Session: 180       Session Title: Poster Session – Breast Cancer – Metastatic       Session Date/Time: June 1, 2026, 1:30-4:30 PM CDT	Shom Goel

 

BG-C9074 (B7-H4-targeting ADC)

 

Abstract Title	Presentation Details	Lead Author
First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion	Rapid Oral Abstract: 3013       Session Title: Rapid Oral Abstract Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology       Session Date/Time: June 2, 2026, 9:45-11:15 AM CDT	Binghe Xu
Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4-targeting ADC) from pharmacokinetics, efficacy and safety perspectives	Poster Session: 166       Session Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology       Session Date/Time: May 30, 2026, 1:30-4:30 PM CDT	Hugh Giovinazzo

 

 

BGB-B2033 (GPC3x4-1BB bispecific antibody)

 

Abstract Title	Presentation Details	Lead Author
A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data	Rapid Oral Abstract: 3016       Session Title: Rapid Oral Abstract Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology       Session Date/Time: June 2, 2026, 9:45-11:15 AM CDT	Hong Jae Chon

 

TEVIMBRA^® (tislelizumab) and ZIIHERA^® (zanidatamab)

 

Abstract Title	Presentation Details	Lead Author
Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: PD-L1 subgroup analysis from HERIZON-GEA-01	Rapid Oral Abstract: 4010       Session Title: Rapid Oral Abstract Session – Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary       Session Date/Time: June 1, 2026, 1:15-2:45 PM CDT	SunYoung Rha
Characterization and management of gastrointestinal adverse events with zanidatamab + chemotherapy ± tislelizumab in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: Analysis from HERIZON-GEA-01	Poster Presentation: 25       Session Title: Poster Session –   Gastrointestinal Cancer-   Gastroesophageal, Pancreatic,   and Hepatobiliary       Session Date/Time: May 30, 2026, 9 AM-12:00 PM CDT	Elena Elimova

 

 

TEVIMBRA^® (tislelizumab)

 

Abstract Title	Presentation Details	Lead Author
RATIONALE-315: Post hoc analysis of event-free survival by surgically relevant subgroups treated with perioperative tislelizumab and neoadjuvant chemotherapy vs neoadjuvant chemotherapy	Poster Presentation: 533       Session Title: Poster Session – Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers       Session Date/Time: May 31, 2026, 9:00 AM-12:00 PM CDT	Gustavo Schvartsman
Quality-adjusted survival comparison for tislelizumab + chemotherapy (CT) versus placebo + CT as first-line treatment in gastric/gastroesophageal junction adenocarcinoma patients with peritoneal metastasis: Long-term follow-up from RATIONALE-305	Poster Presentation: 17       Session Title: Poster Session – Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary       Session Date/Time: May 30, 2026, 9:00 AM-12:00 PM CDT	Rutika Mehta
A novel Bayesian approach for assessing associations between ECOG performance status and patient-reported outcomes in patients with gastric or gastroesophageal junction adenocarcinoma: Post hoc analysis from the RATIONALE-305 trial	Abstract Number: e16044	Marcia Cruz-Correa

 

 

Ociperlimab

 

Abstract Title	Presentation Details	Lead Author
Exploratory biomarker analysis of ociperlimab plus tislelizumab in patients with PD-L1-positive non-small cell lung cancer in AdvanTIG-105	Poster Session: 361       Session Title: Poster Session – Developmental Therapeutics – Immunotherapy       Session Date/Time: May 30, 2026, 1:30-4:30 PM CDT	Jun Zhang

 

BGB-A3055 (anti-CCR8)

 

Abstract Title	Presentation Details	Lead Author
A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors	Poster Session: 313       Session Title: Poster Session – Developmental Therapeutics – Immunotherapy       Session Date/Time: May 30, 2026, 1:30 PM-4:30 PM CDT	Judith Raimbourg

 

 

Full list of BeOne’s presentations at EHA:

 

Zanubrutinib

 

 

Abstract Title	Presentation Details	Lead Author
Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 years) treatment naïve CLL/SLL patients, including those with del(17p): Subgroup analysis from the SEQUOIA trial	Publication Number: PS1703       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Alessandra Tedeschi
Subsequent therapies and time to second progression-free survival events in chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab	Publication Number: PF601       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Mazyar Shadman
Zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL): Implications for interpreting fixed-duration treatment outcomes from CLL17	Publication Number: PS1718       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Talha Munir
Associations between ECOG performance status and patient-reported outcomes in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: Post hoc analysis from the ALPINE trial	Publication Number: PS2492       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Nicole Lamanna
A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: A post hoc analysis of ALPINE	Publication Number: PF1398       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Loic Ysebaert
Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy	Publication Number: PF618       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Jing-Zhou Hou
Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia: Real-world evidence from the United States	Publication Number: PS2516       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Prashant Kapoor
Real-world comparative analysis of treatment discontinuation with covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia	Publication Number: PS1710       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Nakhle Saba
Real-world treatment and survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States	Publication Number: PF608       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Ryan Jacobs
A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States	Publication Number: PS2040       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Yucai Wang
Clinical outcomes among patients with relapsed/refractory mantle cell lymphoma receiving zanubrutinib or acalabrutinib in real-world practice in the United States	Publication Number: PF958       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Javier Munoz
Real-world impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization in patients with chronic lymphocytic leukemia	Publication Number: PS2515       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Rhys Williams
Treatment burden among patients aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma	Publication Number: PF605       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Daniel Ermann
Real-world effectiveness and safety of zanubrutinib in Waldenström macroglobulinemia: Results from the Belgian WIZARD study	Abstract Number: PB3600	Willem Daneels
Real-world experience with zanubrutinib in chronic lymphocytic leukaemia – patient profile, treatment patterns, and safety: Preliminary analysis of French ROZALY study	Abstract Number: PB2898	Florian Bouclet
BRUMIZE: Real-world zanubrutinib use and preliminary safety in R/R marginal zone lymphoma in Europe	Abstract Number: PB3632	Côme Bommier
Indirect comparison of zanubrutinib vs acalabrutinib and ibrutinib efficacy in patients with treatment-naïve chronic lymphocytic leukemia	Abstract Number: PB2895	Mazyar Shadman
Patient-reported outcomes and disease progression in chronic lymphocytic leukemia and small lymphocytic lymphoma: A systematic literature review and gap analysis	Abstract Number: PB2909	Loic Ysebaert
Understanding patients’ perspectives and preferences regarding first-line chronic lymphocytic leukemia treatment across Europe	Abstract Number: PB2934	Lydia Scarfò
Number of deaths avoided with use of zanubrutinib versus ibrutinib for the treatment of chronic lymphocytic leukemia in Europe	Abstract Number: PB2944	Talha Munir
Real-world intravenous immunoglobulin utilization in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with venetoclax plus obinutuzumab vs zanubrutinib	Abstract Number: PB2915	Nicole Lamanna
Real-world outcomes among Medicare beneficiaries treated with first-line Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia	Abstract Number: PB2901	Daniel A. Ermann
Exploring the patient and hematologist preference of treatment characteristics for chronic lymphocytic leukemia: A qualitative study in Europe	Abstract Number: PB4474	Lydia Scarfò

 

Sonrotoclax

 

Abstract Title	Presentation Details	Lead Author
First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53	Publication Number: S145       Session: s424 Prognostication and first line therapy in CLL       Session Date/Time: June 12, 2026   17:15 – 18:30 CEST	Chan Y. Cheah
Updated safety and efficacy of all-oral sonrotoclax + zanubrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including patients with del(17p)/TP53	Publication Number: PS1697       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Stephen S. Opat
Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib in patients with relapsed/refractory mantle cell lymphoma: Results from a phase 1/1b study	Publication Number: PF933       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Jacob D. Soumerai
Phase 1/2 study of sonrotoclax (BGB-11417) monotherapy in Bruton tyrosine kinase inhibitor–pretreated relapsed/refractory mantle cell lymphoma: A Chinese subpopulation analysis	Publication Number: PF961       Session: Poster Session 1       Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST	Yuqin Song
Sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + acalabrutinib in treatment-naive chronic lymphocytic leukemia: A phase 3 randomized trial design (CELESTIAL-TNCLL-2)	Abstract Number: PB2966	Mazyar Shadman
Efficacy of sonrotoclax versus pirtobrutinib in post–Bruton tyrosine kinase inhibitor relapsed/refractory mantle cell lymphoma: An indirect comparison	Abstract Number: PB3626	Toby A. Eyre
Navigating the post–covalent Bruton tyrosine kinase inhibitor landscape in mantle cell lymphoma: Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization	Abstract Number: PB3617	Toby A. Eyre
Risk of tumor lysis syndrome among venetoclax-treated patients with chronic lymphocytic leukemia or mantle cell lymphoma: A real-world study	Abstract Number: PB2896	Alessandra Ferrajoli

 

 

BGB-16673

 

Abstract Title	Presentation Details	Lead Author
BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: A phase 1 CaDAnCe-101 study update	Publication Number: S152       Session: s449 Novel therapies in relapsed/refractory CLL       Session Date/Time: June 14, 2026   11:00 – 12:15 CEST	Stephan Stilgenbauer
Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the phase 1 CaDAnCe-101 study	Publication Number: PS1693       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Irina Mocanu
BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory Waldenström macroglobulinemia: A phase 1 CaDAnCe-101 study update	Publication Number: PS2033       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Judith Trotman
BGB-16673, a Bruton tyrosine kinase degrader, has low risk of CYP3A-mediated drug-drug interaction (DDI): Phase 1 absorption, distribution, metabolism, and excretion and DDI study results	Publication Number: PS1711       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Judith Trotman
BGB-16673 versus idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: The phase 3 CaDAnCe-302 trial	Abstract Number: PB2925	Paolo Ghia

 

 

Tislelizumab

 

Abstract Title	Presentation Details	Lead Author
Evaluation of PET-CT metrics and pharmacokinetics in adults receiving tislelizumab for relapsed/refractory classical Hodgkin lymphoma: Ancillary analyses of LYSA phase 2 TIRHOL study BGB-A317-210	Publication Number: PS2028       Session: Poster Session 2       Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST	Hervé Ghesquières

 

 

About BRUKINSA^® (zanubrutinib)

 

BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

 

 

With the broadest label globally, BRUKINSA is the foundational BTK inhibitor. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing and the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study.

 

 

The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.

 

 

About BEQALZI^™ (sonrotoclax)

 

 

BEQALZI^™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. BEQALZI has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,200 patients have been enrolled across the broad sonrotoclax global development program.

 

 

About BGB-16673

 

 

BGB-16673 is a foundational and potential first-in-class and best-in-class Bruton’s tyrosine kinase (BTK) degrader for the treatment of B-cell malignancies. With 1,100+ patients dosed to date in an extensive global clinical development program, BGB-16673 is the most advanced BTK degrader in the clinic. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025. Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, BGB-16673 is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.

 

 

The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted BGB-16673 PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.

 

 

About ZIIHERA (zanidatamab)

 

 

ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.¹

 

 

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.

 

 

ZIIHERA is a registered trademark of Zymeworks BC Inc.

 

 

About TEVIMBRA (tislelizumab)

 

 

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

 

 

TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 15,000 patients enrolled to date in 30+ countries and regions across 71 trials, including 21 registration-enabling studies. TEVIMBRA is approved in over 50 countries, and more than 2 million patients have been treated globally.

 

 

Select Important Safety Information for BRUKINSA® (zanubrutinib)

 

 

Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury).

 

 

In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

 

 

Please see full U.S. Prescribing Information including U.S. Patient Information.

 

 

Select Important Safety Information for BEQALZI^TM (sonrotoclax)

 

 

Serious and sometimes fatal adverse reactions have occurred with BEQALZI, including tumor lysis syndrome (TLS), serious infections, neutropenia, and embryo-fetal toxicity. BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome.

 

 

In the safety population (N=115), tumor lysis syndrome occurred in 7% of patients who followed the recommended dose ramp-up. Serious infections occurred in 14% of patients, and Grade 3 or 4 infections occurred in 17% (fatal: 2.6%), with pneumonia (10%) being the most common Grade 3 or greater infection. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4: 6%), and febrile neutropenia occurred in 1.7% of all patients. The most common adverse reactions (≥15%) were pneumonia (16%) and fatigue (16%). The most common Grade 3–4 laboratory abnormalities (≥15%) were decreases in lymphocytes (29%) and neutrophils (18%).

 

 

Please see full Prescribing Information.

 

 

Select Important Safety Information for TEVIMBRA

 

 

Serious and sometimes fatal adverse reactions occurred with TEVIMBRA treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

 

 

Please see full U.S. Prescribing Information including the U.S. Medication Guide.

 

 

The information provided in this press release is intended for a global audience. Product indications vary by region.

 

 

About BeOne

 

 

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

 

 

Forward-Looking Statement

 

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s ability to advance future regiments and lead in hematology; BeOne’s ability to build durable disease area leadership in solid tumors; BeOne’s clinical development plans for various programs; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

 

 

To access BeOne media resources, please visit our Newsroom site.

 

 

____________________ 1 ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.).

 

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521195975/en/

 

Business Wire India

Acuity Analytics today announced the launch of Agent Fleet Pro, its next-generation, domain-led Agentic AI platform designed to help financial institutions move from fragmented experimentation to scalable, enterprise-wide value.

Already trialled with 30 clients over the past year, Agent Fleet Pro will now be made available across Acuity Analytics’ global customer base of more than 600 financial institutions.

As adoption of AI gathers pace across the financial sector, many organisations remain constrained by fragmented pilot programmes and stand-alone tools, often lacking impact, control or operational trust. Acuity Analytics seeks to address this gap by embedding AI agents directly into structured workflows, operating alongside human expertise to ensure accountability and purpose at every stage of delivery.

“AI can accelerate individual tasks, but it does not, on its own, transform how an organisation operates,” said Jon O’Donnell, Chief Operating Officer at Acuity Analytics. “Sustainable value comes when the way that work gets carried out is reimagined, whilst applying AI by people who understand the data, regulation and real-world consequences of decisions. Outputs must be explainable and defensible before they reach production – and this requires human judgement at the centre.”

Unlike technology first approaches, Acuity Analytics’ platform begins with business priorities, identifying AI use cases based on value, feasibility and risk before embedding them into critical workflows. This approach is grounded in more than two decades of experience supporting front, middle and back‑office functions across banking, asset management and private markets.

“In financial services, AI only scales when domain expertise stays central to delivery,” said Emma Crabtree, Chief Revenue Officer at Acuity Analytics. “Regulation, data quality and operational nuance cannot be learned in isolation. That’s why our analysts are embedded directly into AI‑enabled workflows, shaping, validating and standing behind the outputs in practice.”

Agent Fleet Pro sits at the heart of Acuity Analytics’ model, providing an agentic execution platform that enables production-ready AI across research, credit, risk, regulatory monitoring, operational and investment workflows.

Designed to be outcome driven rather than tool led, Agent Fleet Pro delivers completed, auditable and explainable research and analysis up to 10x faster, seamlessly integrating with clients’ existing technology environments. By combining advanced AI with human expertise, the model enables organisations to move confidently from pilot programmes to fully operational, scaled deployments.

Agent Fleet Pro can be deployed flexibly, either embedded within a client’s environment or fully managed by Acuity Analytics with client oversight. It integrates with enterprise data platforms, leading large language models, and core client systems, with governance, validation, and auditability incorporated by design to meet financial services standards. This architecture maintains robust control, transparency, and compliance.

In early deployments, Agent Fleet Pro has demonstrated measurable efficiency gains, helping internal analysis teams improve accuracy and operational efficiency by approximately 20-40% across critical use cases.

With a technology agnostic delivery model and human expertise deployed throughout the AI lifecycle, Acuity Analytics aims to help financial institutions turn AI investment into durable competitive advantage, moving decisively from ambition to outcomes.

Business Wire India

NoBroker Packers and Movers, the relocation services division of NoBroker (India’s first proptech unicorn), is setting a new standard for organised, technology-driven home shifting in Bangalore, emerging as one of the city’s highest-rated and most trusted moving platforms at a time when India’s relocation industry is experiencing rapid structural growth. According to the ShiftingApp India Moving Industry Report 2026, the sector reached INR 90,016 crore in FY 2025–26 (growing 14.2% year-over-year) and facilitated over 8.2 million relocations during the fiscal year. Projections suggest the market will expand to INR 1,58,000 crore by 2030, driven by urbanisation, corporate expansion, and the accelerating shift toward technology-enabled booking platforms.

 

Yet for all its scale, the industry remains deeply fragmented. Organised players currently account for only approximately 35% of the total market, leaving the majority of consumers navigating an unstructured landscape of unverified operators, opaque pricing, and minimal post-service accountability.

 

Bangalore sits at the epicentre of this demand surge. A Savills India report published in May 2025 identified Bengaluru as likely to emerge as the world’s fastest-growing major city through 2035, with the city’s metro population already reaching approximately 14.4 million in 2025, adding an estimated 400,000 residents every year. The city recorded 28.7 million square feet of office leasing in 2025, with demand anchored substantially by Global Capability Centres (GCCs) expanding into the city.

 

For relocation services, this translates directly into rising demand and heightened expectations. Professionals relocating into and within Bangalore require moving partners who can meet timelines, protect belongings, and operate transparently. Against this backdrop, the market gap left by unorganised operators has become commercially and structurally significant.

 

DIGITAL PLATFORMS RESHAPING THE MOVING INDUSTRY

The shift toward organised, technology-driven relocation services is accelerating across India. According to the ShiftingApp India Moving Industry Report 2026, online booking platforms captured 23% of total moving bookings in FY 2025–26 (up sharply from 11% in 2023), representing approximately INR 20,704 crore in gross merchandise value. Customers using digital platforms report 32% higher satisfaction scores and 28% lower costs, attributable to pricing transparency absent from the unorganised segment.

 

This digital adoption trend aligns directly with NoBroker’s platform-first model. The company’s decade-long investment in technology infrastructure (from real-time tracking to centralised customer support and documented claims processes) has positioned it ahead of the curve as consumer behaviour migrates toward accountable, verifiable service providers.

STRUCTURED RESPONSE TO A STRUCTURAL GAP

NoBroker Packers and Movers, the relocation services division of NoBroker (India’s first proptech unicorn), has positioned itself as a direct answer to these systemic market failures. Operating through a verified partner vendor network across 100+ cities and 10,000+ localities, the platform has completed over 15 lakh relocations and reports a 99.3% accuracy rate on damage-free, on-time deliveries.

 

The company’s model addresses the industry’s core consumer pain points (pricing opacity, unverified labour, and absent post-service support) through three structural mechanisms:

 

• Upfront quotation with no hidden charges, committed at the point of booking
• Background-verified moving teams onboarded through a structured vendor vetting process
• A designated Quality Service Expert is assigned to each move, managing the process end-to-end

 

The platform holds ISO 9001:2015 certification and has received the Confederation of Indian Industry (CII) Award for Industry Transformation in Logistics and Supply Chain, as well as the BW Supply Chain World recognition for Best Collaborative Supplier Partnership; institutional acknowledgements that reflect external validation of its operational model.

 

“Our priority has always been to bring structure, transparency, and accountability to a market that has historically offered residents very little of either. We continue to invest in tightening vendor quality controls and improving claims resolution timelines, because we recognise that a platform-based model places the quality of the customer experience in the hands of those on the ground.”

— Akhil Gupta, Co-Founder & Chief Technology Officer, NoBroker

PERFORMANCE METRICS IN BANGALORE OPERATIONS

NoBroker Packers and Movers’ aggregate Google Business listing for Bangalore carries a 4.6-star rating from 600+ verified reviewers. Neighbourhood-level listings across the city reflect consistent performance across geographically distinct markets:

 

• Ramamurthy Nagar – 48 reviews with an impressive 4.8-star rating.
• Hosa Road – 150+ reviews and a strong 4.5-star rating.
• Indiranagar – 37 reviews with a reliable 4.5-star rating.
• Banashankari – 77 reviews and a solid 4.4-star rating.
• Electronic City – 33 reviews with a 4.1-star rating.
• Main Bangalore Listing – 600+ reviews and an excellent overall 4.6-star rating.
   

Source: Google Maps Business Listings, NoBroker Packers and Movers Bangalore (verified, 2025)

 

The pattern is consistent across third-party review platforms. On Justdial, ratings range between 4.2 and 4.6 stars across Bangalore listings, with 100–500+ reviews per branch. On MouthShut, the platform maintains an average of 4.56 stars nationally, with an estimated 93% positive sentiment across 2 lakh+ reviews. Sulekha listings range from 4.0 to 4.5 stars with balanced, positive feedback focused on service quality.

 

CUSTOMER EXPERIENCE

Customer feedback across platforms reveals consistent themes. Pricing transparency is the most frequently cited driver of initial booking decisions, particularly among customers with prior negative experiences with informal operators.

Repeat usage represents a stronger signal: customers who use the service for intra-city moves frequently return for intercity relocations, citing service reliability rather than cost as their primary motivation. The platform offers up to 25% discounts on within-city and between-city shifts.

 

“The team arrived within the scheduled window and completed packing with proper material protection. There were no charges beyond the agreed quote, and the move was completed without any damage to our belongings.”

 

Priya Venkataraman, Senior Software Engineer

(Within-City Relocation, Indiranagar)

 

“I had previously used an informal mover and lost several items in transit. With NoBroker Packers and Movers, the process was documented from the start. Glassware and fragile items were wrapped individually and arrived intact.”

 

Rohan Mehta, Product Manager

(Intercity Relocation, Pune to Bangalore)

Community forums (particularly Reddit threads in r/PackersMoversBLR) surface a more unfiltered perspective than platform-hosted reviews. This feedback is genuinely positive, which is itself instructive.

 

“I moved from Whitefield to HSR Layout last month and was honestly worried about Bangalore traffic and delays. I checked a few NoBroker packers and movers in Bangalore review posts before booking. The team arrived on time and handled the move efficiently, which made things easier.”

– Cutillustrious5040

 

“A colleague recommended going through a NoBroker packers and movers in Bangalore review before finalising any service. I booked them for my 1BHK shift, and the experience was quite decent. The packing and loading were done properly.”

 

– Bookishrory

Testimonials Shared By Trusted Customers

Hear directly from the customers across Bangalore as they share their real experiences and satisfaction with our services:

• www.youtube.com/shorts/CKaq6ryYUZ4
• https://www.instagram.com/reels/DKCnfwgCcoz/
• https://www.instagram.com/reels/DJwqVLgiqWJ/

 

SERVICE CONSISTENCY

 

No platform operating at this scale is without service variability. Occasional delays during peak relocation periods and communication gaps between assigned vendors and customers appear in the feedback landscape.

 

NoBroker’s stated response is structural rather than ad hoc: dedicated escalation pathways, a documented claims resolution process, and a 100% Damage & Delay Protection commitment — Any Damage, Any Delay, We Pay.

 

The company’s ongoing investment in vendor quality controls reflects an acknowledgement that platform-model accountability ultimately depends on ground-level execution.

 

With the organised relocation sector projected to grow at a 12–15% CAGR through 2030, and Bangalore’s population and corporate footprint continuing their upward trajectory, the structural demand for accountable, technology-enabled moving services is unlikely to plateau. Platform-led models that apply verified vendor networks, upfront pricing, and post-service accountability are increasingly relevant, not as a premium offering, but as a baseline consumer expectation in India’s largest professional migration markets.